Sponsor · clinical trials

Anna Raciborska clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Poland register with Anna Raciborska as lead sponsor. Synced 12 Nov 2026

5Current trials

2Recruiting now

6Drugs in these trials

1Trial register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 12 Nov 2026 · Editorial standards

At a glance

Anna Raciborska is the lead sponsor of 5 current clinical trials in our Poland register. 2 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Fluorodeoxyglucose, Mifamurtide and Naxitamab. The most-studied condition is Histiocytosis.

ClinicalTrials.gov trials by status

Recruiting240%
Active, closed360%

Trials by phase

Phase 2480%
Phase 3120%

Clinical trials sponsored by Anna Raciborska

5 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) NCT05968768 · ClinicalTrials.gov ↗ · Ewing Sarcoma Drug: Naxitamab	Phase 2	Recruiting	2023-10	Poland
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma NCT07787429 · ClinicalTrials.gov ↗ · Osteosarcoma Drugs: Mifamurtide, Sorafenib	Phase 2	Recruiting	2026-04	Poland
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis NCT04943198 · ClinicalTrials.gov ↗ · Histiocytosis Drug: Vemurafenib	Phase 2	Active, closed	2021-04	Poland
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients NCT04943224 · ClinicalTrials.gov ↗ · Histiocytosis Drug: Trametinib	Phase 2	Active, closed	2021-04	Poland
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging NCT04943211 · ClinicalTrials.gov ↗ · Histiocytosis Drug: Fluorodeoxyglucose	Phase 3	Active, closed	2021-04	Poland

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Anna Raciborska trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Fluorodeoxyglucose1 Mifamurtide1 Naxitamab1 Sorafenib1 Trametinib1 Vemurafenib1

Conditions in Anna Raciborska trials

3 conditions

Histiocytosis3Ewing Sarcoma1 Osteosarcoma1

By trial register

Register	Trials	Recruiting
Clinical trials in Poland	5	2

A trial with sites in more than one country appears in each of those registers.

Questions about Anna Raciborska trials

How many clinical trials does Anna Raciborska sponsor?

Anna Raciborska is the lead sponsor of 5 current trials on ClinicalTrials.gov in our Poland register, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.

Are Anna Raciborska trials recruiting?

Yes. 2 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Anna Raciborska testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are Fluorodeoxyglucose (1), Mifamurtide (1), Naxitamab (1), Sorafenib (1) and Trametinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.